Overweight, Obesity
Conditions
Keywords
Overweight, Obesity, Maridebart Cafraglutide, AMG 133, QT/QTc Intervals
Brief summary
The main objective of this trial is to evaluate the effect of maridebart cafraglutide subcutaneously (SC) on the placebo-corrected, change from baseline in QT interval corrected for heart rate using Fridericia's formula in participants living with overweight or obesity.
Interventions
Participants will receive maridebart cafraglutide SC.
DRUGMoxifloxacin
Participants will receive moxifloxacin orally.
Participants will receive placebo for maridebart cafraglutide SC.
Participants will receive placebo for moxifloxacin orally.
Sponsors
Amgen
Study design
Allocation
RANDOMIZED
Intervention model
CROSSOVER
Primary purpose
BASIC_SCIENCE
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
No
Inclusion criteria
To take part in the trial, participants must meet all of the following: 1. Provide signed and dated informed consent before any trial procedures. 2. Be able to understand the trial requirements, sign the consent form, and follow trial restrictions. 3. Male or female, of any race, between 18 and 60 years old (inclusive). * Females must not be pregnant or breastfeeding. * Males and females who could become pregnant must agree to use effective birth control as specified in the protocol. 4. Body mass index (BMI) between 25.0 and 35.0 kg/m\^2 (inclusive). 5. No major changes in diet or lifestyle in the past 3 months, based on self-report. 6. Stable body weight (less than 5 kg change) in the past 3 months, based on self-report. 7. Blood potassium, calcium, and magnesium within the normal range at screening and at check-in for the first treatment period. 8. Participants with controlled high blood pressure, cholesterol problems, or hypothyroidism on stable treatment for at least 3 months may be included (except for medicines known to affect heart rhythm or interact with moxifloxacin). Other mild, stable health conditions may be allowed with approval from the investigator and medical monitor.
Exclusion criteria
Participants will not be able to take part if they meet any of the following: Medical Conditions 1. Any significant medical condition or abnormal test result that, in the opinion of the investigator, could pose a risk or interfere with trial participation. 2. History of diabetes (any type, except past gestational diabetes), or Haemoglobin A1c (HbA1c) ≥ 6.5% at screening. 3. History of pancreatitis within the past year, or high blood tests suggesting pancreatic problems (lipase/amylase \> 2× normal, or fasting triglycerides \> 500 mg/dL). 4. Liver enzymes (alanine aminotransferase \[ALT\] or aspartate aminotransferase \[AST\]) more than 2× the upper limit of normal. 5. Kidney function (estimated glomerular filtration rate \[eGFR\]) \< 70 mL/min/1.73 m\^2. 6. Cancer within the last 5 years (except treated nonmelanoma skin cancers or in situ cervical/breast lesions). 7. Personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2. 8. Uncontrolled thyroid disease (abnormal thyroid-stimulating hormone \[TSH\] outside 0.4-6.0 mIU/L). 9. Contraindications to moxifloxacin, including history of tendon disorders with quinolone use. 10. History of gastrointestinal surgery or disease that may affect absorption of oral drugs (other than uncomplicated appendectomy or hernia repair). 11. Inability to swallow pills. 12. History of significant esophageal, stomach, or bowel disorders (eg, ulcers, bleeding, Crohn's disease, ulcerative colitis, irritable bowel syndrome, gastroparesis). 13. Current or recent suicidal thoughts (per Columbia Suicide Severity Rating Scale \[C-SSRS\]). 14. Lifetime history of suicide attempt or behavior. 15. Major depressive disorder within the past 2 years. 16. History of other serious psychiatric disorders (eg, schizophrenia, bipolar disorder). 17. High depression score (patient health questionnaire-9 \[PHQ-9\] ≥ 15). 18. History or current signs of heart disease (eg, heart attack, congenital defects, valve disease, angina, bypass or stent). 19. History of ischemic optic neuropathy (eye damage from poor blood flow). 20. Diagnosis of sleep apnea. Diagnostic Tests 21. Positive test for human immunodeficiency virus (HIV). 22. Positive test for hepatitis B or C (exceptions apply for prior vaccination or resolved infection). 23. Abnormal vital signs: average blood pressure \> 140/90 mmHg or \< 90/50 mmHg, or heart rate \> 110 or \< 40 bpm. 24. Abnormal ECG findings at screening or check-in, including: * QTcF \> 450 ms (males) or \> 470 ms (females). * QRS \> 120 ms, PR \> 220 ms, AV block (2nd or 3rd degree). * Findings that make QTc measurement unreliable. * Risk factors for dangerous arrhythmias (eg, heart failure, low potassium, long QT syndrome). * Clinically significant arrhythmias. Medications 25. Use of drugs that affect absorption, metabolism, or elimination within 30 days of dosing. 26. Use of drugs known to prolong QT/QTc within 30 days of dosing. 27. Use of prescription drugs (other than hormone replacement or contraception) within 14 days of dosing. 28. Use of long-acting/slow-release medicines still active within 14 days of dosing. 29. Use of non-prescription products (vitamins, supplements, herbal products) within 7 days of dosing. 30. Use of glucagon-like peptide-1 (GLP-1) or glucose-dependent insulinotropic polypeptide (GIP) receptor agonists/antagonists within 3 months of check-in. Other Clinical Trial Experience 31. Participation in another investigational drug trial within 30 days or 5 drug half-lives (whichever is longer). 32. Previous exposure to maridebart cafraglutide in this or another trial. Lifestyle 33. Alcohol use \> 21 units/week (men) or \> 14 units/week (women). 34. Alcohol use within 48 hours before check-in. 35. Positive drug screen or alcohol test at screening or check-in. 36. History of alcohol or drug abuse within 1 year. 37. Use of tobacco/nicotine products within 3 months, or positive cotinine test. 38. Use of caffeine within 48 hours of screening or check-in. 39. Consumption of grapefruit, Seville orange, or related products within 7 days of check-in. 40. Consumption of poppy seed-containing foods within 7 days of check-in. Other 41. Receipt of blood products within 2 months before check-in. 42. Blood donation within 3 months; plasma donation within 2 weeks; platelet donation within 6 weeks. 43. Poor veins for blood draws. 44. Any other reason, in the opinion of the investigator, the participant should not take part.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change from Baseline in QTcF for Maridebart Cafraglutide | Up to Day 171 | Change from baseline in QTcF for maridebart cafraglutide will be the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after maridebart cafraglutide dosing. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Area Under the Concentration-time Curve Over the Dosing Interval (AUCtau) of Maridebart Cafraglutide | Up to Day 171 | — |
| Maximum Observed Concentration (Cmax) of Maridebart Cafraglutide | Up to Day 171 | — |
| Change from Baseline in Heart Rate | Up to Day 171 | Change from baseline in heart rate will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in HR for the by-time point analysis. |
| Change from Baseline in PR Interval | Up to Day 171 | Change from baseline in PR Interval will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in PR for the by-time point analysis. |
| Change from Baseline in QRS Duration | Up to Day 171 | Change from baseline in QRS Duration will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QRS for the by-time point analysis. |
| Categorical Outliers for QTcF | Up to Day 171 | — |
| Categorical Outliers for HR | Up to Day 171 | — |
| Categorical Outliers for PR | Up to Day 171 | — |
| Categorical Outliers for QRS | Up to Day 171 | — |
| Number of Participants with Treatment-emergent Changes in Electrocardiogram (ECG) Morphology | Up to Day 171 | — |
| Change from Baseline in QTcF for Moxifloxacin | Up to Day 171 | Change from baseline in QTcF for moxifloxacin will be used as the dependent variable for calculation of model-derived placebo-corrected, change from baseline in QTcF after moxifloxacin dosing for both the assay sensitivity and by-time point analysis. |
| Number of Participants with Anti-maridebart Cafraglutide Antibody Formation | Up to Day 232 | — |
| Number of Participants with Treatment-emergent Adverse Events and Serious Adverse Events | Up to Day 232 | — |
Countries
United States
Contacts
STUDY_DIRECTORMD
Amgen
Outcome results
None listed